Join us at PSCC Innovation Forum 2024
Today, the Paris Saclay Cancer Cluster kicks off its inaugural “Innovation Forum 2024” at the Faculty of Medicine Paris-Saclay. 🚀 We’re excited to start this day dedicated to scientific discoveries, engaging exchanges, and fostering collaboration within our ecosystem. 🤝 We look forward to meet experts, researchers, industry professionals, start-ups, patients, platform developers… in the fight against cancer. Let’s share this moment of science, connections, and conviviality! hashtag#PSCCInnovationForum hashtag#CancerResearch hashtag#ScienceCommunity Université Paris-Saclay, Sanofi, Inserm, Institut Polytechnique de Paris, Gustave Roussy, Institut Curie, AP-HP, Assistance Publique – Hôpitaux de Paris, Unicancer, Hôpitaux Saint-Joseph & Marie-Lannelongue, Hopital Foch
🔔 Project Update | Allogenix Consortium 🔔
🔔 Project Update | Allogenix Consortium 🔔 Our Oncology and Immunology team spent a productive day with our 🤝 partners from InSphero, during which they discussed the progress of the joint Allogenix consortium. 🚀 Launched in November 2022 with a duration of 3 years, the project, funded by the #EUROSTARS Programme, aims to develop a companion test for the next-generation cancer cell #immunotherapy STC-1010. ❗️STC-1010 is the 1st asset from Brenus Pharma‘s unique STC “off-the-shelf” discovery platform (Stimuated-Tumor-cells : Shared Stimulated & Haptenized Cancer related proteins) targeting #colorectalcancer 🤩 We are thrilled to report promising preliminary results, which have fuelled the advancement to the next development stage. 🤝 It’s a true pleasure collaborating with the experts from InSphero, as we work together to pursue the ambitious goal of developing a❗️first-in-class allogeneic cell vaccine against cancer❗️ 🔜 Stay tuned for more updates from the Allogenix project contributors: Benoit Pinteur, George Alzeeb, lionel Chalus, Léa Perles, Wolfgang Moritz, Irina Agarkova, Laure-Anne Ligeon, Simon Stroebel, PhD, Michał Rudnik, Maja Nedic, Marion Bavand, Marion Brun, Jan Lichtenberg, Paul Edgard Clémençon, Madhu Lal Nag, MBS PhD #colorectalcancer #consortium #partnership #biotechnology #pharma
🎬 BEHIND THE SCENE – Léa Perles : Strategic Operation Lead
🎬 BEHIND THE SCENE – Léa Perles (PharmD, MSc) Plongez dans l’aventure, racontée par celles et ceux qui la vivent. SEE VIDEO Dans cette interview, Léa partage son parcours; et son envie d’innover en industrie #pharmaceutique dans une startup comme Brenus Pharma. En tant que chargée de Business développement et Partenariats stratégiques, elle met en œuvre la stratégie de développement de Brenus, et s’implique pour faire rayonner nos #collaborations. ☀️🤝 ➡️ In this interview, Léa shares her career path and her desire to innovate in the #pharmaceutical industry in a startup like Brenus Pharma. As Lead of Business Development and Strategic Partnerships, she implements Brenus’ development strategy, and is committed to making our collaborations shine. #BehindTheScene #DareToInnovate Crédit vidéo : https://lets-up.fr/ 📍Cardinal Workside 60 Quai Perrache 69002 – LYON (FR)
Happy New Year 2024 !
Ready for an exciting and thrilling 2024 ! 🚀🟣🧬 Toute l’équipe de Brenus Pharma vous présente ses meilleurs voeux pour la nouvelle année. 🎇 L’année 2023 a été riche en défis, mais toujours ponctuée de fortes rencontres et d’efforts collectifs afin d’ouvrir la voie pour 2024 où nous souhaitons et espérons accomplir de grands succès : → Lancement du premier essai clinique et inclusion des premier patients. → Scale-up industriel. → Etendre la plateforme STC avec le développement d’un nouveau produit. → Renforcer les collaborations et faire rayonner la biotechnologie française. En 2024, nous continuerons de cultiver l’esprit de collaboration comme un véritable moteur d’innovation. 🤝 Un grand merci à nos anciens, nouveaux et futurs partenaires, qui nous permettent de faire vivre le projet. Plus que jamais, nous continuerons d’unir nos forces. #DareToInnovate —————————————————— The entire team of Brenus Pharma presents its best wishes for the new year. 🎇 2023 was a year full of challenges, but always punctuated by strong encounters and collective efforts to pave the way for 2024 where we hope to achieve great success: → Launching the first clinical trial and enrolling first patients. → Industrial scale-up. → Expanding the platform with the development of a new product. → Strengthening collaborations and promoting French biotechnology. In 2024, we will continue to foster a spirit of collaboration as a real driver of innovation. 🤝 A big thank you to our former, new and future partners, who allow us to keep the project alive. More than ever, we will continue to unite our forces. #DareToInnovate #BrenusPharma #NewYear #Innovation #Healthcare #Research #Collaboration
[📢PSCC : Let’s collaborate at the heart of innovation in oncology 🚀]
DOWNLOAD PRESS RELEASE 🚀 Let’s collaborate at the heart of innovation in oncology. 🚀 Thrilled to share that Brenus Pharma is now part of the Paris Saclay Cancer Cluster (PSCC) (PSCC), the first national #Oncocluster! 🌐 We are proud to be part of the national and European oncology innovation ecosystem. By combining PSCC’s strengths and Brenus’ technology, we aim to foster #collaborations and accelerate our shared mission to improve #patient care. ➡️ Excited to contribute to PSCC’s collective ambition in reshaping the future of oncology! 🌍💪 #BrenusPharma #OncologyInnovation #PSCC #NextGenerationEU
[📢Stimulated Tumor Cells (STC) vaccine induces response in colorectal cancer #SITC23]
DOWNLOAD PR 🔬#SITC23 Thrilled to share new results we presented at the Society for Immunotherapy of Cancer (SITC) Congress! 🌎 Many thanks to all contributors, Céline Gongora Corentin Richard Romain Boidot Tanguy Fortin Alban Bessede Yan WANG Italiano Antoine Based on these vaccine characterization and preclinical, in-ovo and ex-vivo efficiency data, STC-1010 treatment will soon be evaluated for the first time in clinical trial in advanced metastatic stage of colorectal cancer in 2024.
SITC 2023 Annual meeting
Stimulated tumor cells (STC) vaccine induce response in colorectal cancer A. Italiano et al, J for ImmunoTherapy of Cancer, 2023 http://dx.doi.org/10.1136/jitc-2023-SITC2023.1132 Link to Poster DOWNLOAD PRESS RELEASE
[#NEXTHealthcare] The NEXT Roadshow is only a week away! 🎉
Thank you to Business France North America to give us this great opportunity to continue dusicussions and connect again with wonderful North American ecosystem 💬 #biotech #pharma Congratulations to all the innovated company selected ! ➡️ We are getting ready to share this week with strong #healthcare actors. [#NEXTHealthcare] The NEXT Roadshow is only a week away! 🎉 🗓️ Between October 16-20, the acceleration program participants will travel to Montreal and Boston to meet potential investors, gain insights from industry leaders and connect with like-minded professionals. Montreal (October 16-17): 💡 Speed meetings with Venture Capitalists. 💼 B2B meetings to forge valuable partnerships. 🌃 A delightful networking night to embrace the vibrant Canadian ecosystem, hosted by our partner Dentons Boston (October 18-20): 🏙️ A visit of Kendall Square, regarded as the health sciences innovation district of the US. 🌟 A networking night to dive into the dynamic US ecosystem hosted by EY 🎤 A pitch session to captivate potential investors hosted by CIC (Cambridge Innovation Center) #Roadshow French Healthcare Louis Malatrait Flavio Carratu Brenus Pharma Algoscope Aurora Sterilisation AXELIFE Intradys INSTITUT DE BIOTECHNOLOGIES JACQUES BOY Vibiosphen Ensweet – solutions de téléréadaptation HypnoVR and Thess Corporate
Join us at #Sachs_BEF
🔬 Dive into the future of cancer treatment! Join us on the 21st of September, 2023 for the ‘Advances in Immuno-Oncology’ panel at the 23rd Annual Biotech in Europe Forum (#Sachs_BEF) 🌍 Mark your calendar and learn about the latest breakthroughs in immuno-oncology from leading industry experts! 📆🎗️ Co-Chaired by: Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG Ekaterina Smirnyagina Smirnyagina, Senior Partner (Life Sciences), Oxford Science Enterprises Panellists: Luc Boblet Co-Founder & CEO, Egle Therapeutics SAS Pascal Winnen Neuville, CEO, DOMAIN Therapeutics SA Paul Bravetti, CEO, Brenus Pharma Per Norlén, CEO, Evaxion Biotech A/S
Panel participation at 23rd Biotech in Europe forum
Paul BRAVETTI ⬇️ “Two enlightening days at the Sachs Associates 23rd BIOTECH IN EUROPE FORUM have left me both #proud and #inspired. 📈 Being part of the “Major advances in immuno-oncology” panel, we delved deep into this year’s progress in this ever-evolving field with a palpable excitement around clinical data, science insights, and the promising directions we’re heading with such approaches. 🔬While we’re making strides with innovative therapies and tools, the ultimate focus remains on translating these into tangible patient benefits. Our shared mission remains to emphasized the pivotal role of understanding the nuanced biology and ensuring it aligns with patient needs. Every step of our work is aimed at optimizing efficacy while also managing expectations, and manufacturing challenges. ☑️ Many thanks to Esteban Pombo-Villar, and Hans Herklots for chairing, and Gerben Moolhuizen, Luc Boblet, Pascal Neuville, Seth Goldblum with whom I had the pleasure of sharing this discussion. Lastly, thank you to the SACHS for their hosting and organization. Such moments solidify my belief in the bright future of immuno-oncology and biotechnology 🟣” Brenus Pharma #CancerResearch #ImmunoOncology #Biotech #Innovation #SACHSForum